Cargando…
Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
Cholangiocarcinoma is the most common primary malignant tumor of the bile duct. The current standard first-line treatment for advanced or metastatic cholangiocarcinoma is gemcitabine and cisplatin. However, few effective treatment choices exist for refractory cholangiocarcinoma, and additional thera...
Autores principales: | Chung, Shin-Yi, Hung, Yi-Ping, Pan, Yi-Ru, Chang, Yu-Chan, Wu, Chiao-En, Hsu, Dennis Shin-Shian, Chang, Peter Mu-Hsin, Lu, Meng-Lun, Huang, Chi-Ying F., Su, Yeu, Hsiao, Michael, Yeh, Chun-Nan, Chen, Ming-Huang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389680/ https://www.ncbi.nlm.nih.gov/pubmed/34440089 http://dx.doi.org/10.3390/biomedicines9080885 |
Ejemplares similares
-
Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022) -
The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019) -
Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation
por: Pan, Yi-Ru, et al.
Publicado: (2023) -
Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients
por: Yeh, Chun-Nan, et al.
Publicado: (2017) -
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)